Target intelligence / Profile preview

Casein kinase I isoform alpha (CK1α) (CK1α)

Target
CK1α
Molecular classification
Enzyme, Serine/threonine-protein kinase, Casein kinase family
01

Overview

Casein kinase I isoform alpha (CK1α), encoded by the CSNK1A1 gene, is a ubiquitous serine/threonine kinase that serves as a central regulator of various signaling pathways, including the Wnt/beta-catenin and p53 pathways (UniProt P48729). It plays a critical role in maintaining cellular homeostasis by phosphorylating key substrates involved in cell cycle progression and DNA damage responses (Kronke et al., 2015, Nature). In the context of hematology, CK1α is a validated therapeutic target for myelodysplastic syndrome (MDS) characterized by the deletion of chromosome 5q [del(5q)], a condition where the CSNK1A1 gene is haploinsufficient (Schneider et al., 2014, Cancer Cell). The immunomodulatory drug lenalidomide functions as a molecular glue that facilitates a de novo interaction between CK1α and the cereblon (CRBN) E3 ubiquitin ligase complex, leading to the selective ubiquitination and proteasomal degradation of CK1α (Petzold et al., 2016, Nature). This degradation triggers a p53-dependent apoptotic response that is particularly lethal to del(5q) MDS cells due to their reduced baseline dosage of the enzyme, providing a mechanism for the clinical efficacy of lenalidomide in this patient population (Fink et al., 2018, Blood).

Other names
CSNK1A1CK1aCasein kinase 1 alphaCKI-alphaHCK1A
02

Mechanism of action

Molecular glue-induced targeted protein degradation via the CRL4-CRBN E3 ubiquitin ligase complex (Kronke et al., 2015, Nature).

03

Biological functions

Signal transductionCell cycleApoptosisWnt signaling regulationp53-mediated DNA damage response
04

Disease associations

CancerMyelodysplastic syndromeAcute myeloid leukemia
05

Safety considerations

NeutropeniaThrombocytopeniaMyelosuppressionPotential for p53-independent resistance mechanisms
06

Interacting drugs

Lenalidomide
07

Biomarkers

5q deletion (del(5q))CRBN expression levelsCK1α protein levels

Beyond the preview

Go deeper on Casein kinase I isoform alpha (CK1α) (CK1α).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Casein kinase I isoform alpha (CK1α) (CK1α).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call